These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 25693591)
1. Editorial: Switching to biological agents in autoimmune and autoinflammatory disorders: current targets and therapy. Gasparyan AY Curr Med Chem; 2015; 22(16):1890-1. PubMed ID: 25693591 [No Abstract] [Full Text] [Related]
2. Introduction to autoinflammatory syndromes and diseases. Abramovits W; Oquendo M Dermatol Clin; 2013 Jul; 31(3):363-85. PubMed ID: 23827242 [TBL] [Abstract][Full Text] [Related]
3. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment. Havnaer A; Han G Am J Clin Dermatol; 2019 Aug; 20(4):539-564. PubMed ID: 30997665 [TBL] [Abstract][Full Text] [Related]
5. Controlling inflammation: contemporary treatments for autoinflammatory diseases and syndromes. Sterba G; Sterba Y Dermatol Clin; 2013 Jul; 31(3):507-11. PubMed ID: 23827252 [TBL] [Abstract][Full Text] [Related]
6. Regulating against the dysregulation: new treatment options in autoinflammation. Kallinich T Semin Immunopathol; 2015 Jul; 37(4):429-37. PubMed ID: 26059720 [TBL] [Abstract][Full Text] [Related]
9. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. de Koning HD; Schalkwijk J; van der Meer JW; Simon A J Allergy Clin Immunol; 2011 Dec; 128(6):1352-4. PubMed ID: 21704363 [No Abstract] [Full Text] [Related]
10. Dermatologic Manifestations of Monogenic Autoinflammatory Diseases. Shwin KW; Lee CR; Goldbach-Mansky R Dermatol Clin; 2017 Jan; 35(1):21-38. PubMed ID: 27890235 [TBL] [Abstract][Full Text] [Related]
12. The body against self: autoinflammation and autoimmunity. Borella E; Palma L; Zen M; Bettio S; Nalotto L; Gatto M; Domeneghetti M; Laccarino L; Punzi L; Doria A Isr Med Assoc J; 2014 Oct; 16(10):608-10. PubMed ID: 25438443 [No Abstract] [Full Text] [Related]
13. Time for a new approach to drug development for rare systemic autoinflammatory diseases. Zitoun NM; Demirkaya E; Goldbach-Mansky R; Romano M Nat Rev Rheumatol; 2024 Jun; 20(6):317-318. PubMed ID: 38565692 [No Abstract] [Full Text] [Related]
14. Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases. Ostrov BE Immunol Invest; 2015; 44(8):777-802. PubMed ID: 26575464 [TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor inhibitors in tumor necrosis factor receptor-associated periodic syndrome: still a chance to work? Rigante D Intern Emerg Med; 2017 Mar; 12(2):269-270. PubMed ID: 27817124 [No Abstract] [Full Text] [Related]
17. JAK inhibition in the type I interferonopathies. Crow YJ; Neven B; Frémond ML J Allergy Clin Immunol; 2021 Oct; 148(4):991-993. PubMed ID: 34375617 [No Abstract] [Full Text] [Related]
18. What do autoinflammatory syndromes teach about common cutaneous diseases such as pyoderma gangrenosum? A commentary. Butler D; Shinkai K Dermatol Clin; 2013 Jul; 31(3):427-35. PubMed ID: 23827245 [TBL] [Abstract][Full Text] [Related]
19. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: From conventional to cutting edge in biologics and RNA- based nanomedicines. Andretto V; Dusi S; Zilio S; Repellin M; Kryza D; Ugel S; Lollo G Adv Drug Deliv Rev; 2023 Oct; 201():115080. PubMed ID: 37660747 [TBL] [Abstract][Full Text] [Related]